These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 29142151)

  • 21. Lusutrombopag as a substitute for platelet transfusion for thrombocytopenia associated with chronic liver disease in a patient undergoing endoscopic spinal surgery: A case report.
    Kaneko T; Takano Y; Ishibashi K
    Medicine (Baltimore); 2021 Jan; 100(2):e24094. PubMed ID: 33466174
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetic Assessment and Treatment Effect of Lusutrombopag in Child-Pugh Class C Patients: Review of Patient Data from Two Clinical Studies and Post-Marketing Surveillance.
    Flamm SL; Peck-Radosavljevic M; Fukuhara T; Bentley R; Katsube T; Ochiai T; Kano T; Tsukimura E; Sasaki R; Osaki Y
    Adv Ther; 2022 Sep; 39(9):4285-4298. PubMed ID: 35904722
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of Anti-GPIIb/IIIa Antibody-Producing B Cells as a Predictor of the Response to Lusutrombopag in Thrombocytopenic Patients with Liver Disease.
    Wada N; Uojima H; Satoh T; Okina S; Iwasaki S; Shao X; Takiguchi H; Arase Y; Itokawa N; Atsukawa M; Miyazaki K; Hidaka H; Kako M; Kagawa T; Iwakiri K; Horie R; Suzuki T; Koizumi W
    Dig Dis; 2021; 39(3):234-242. PubMed ID: 32759604
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Partial splenic embolization for thrombocytopenia in liver cirrhosis: predictive factors for platelet increment and risk factors for major complications.
    Cai M; Huang W; Lin C; Li Z; Qian J; Huang M; Zeng Z; Huang J; Shan H; Zhu K
    Eur Radiol; 2016 Feb; 26(2):370-80. PubMed ID: 26002134
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of predictors after partial splenic embolization for thrombocytopenia with liver cirrhosis.
    Ishikawa T; Ohashi K; Kodama E; Kobayashi T; Azumi M; Nozawa Y; Iwanaga A; Sano T; Honma T
    Medicine (Baltimore); 2022 Oct; 101(40):e30985. PubMed ID: 36221332
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of the effect of partial splenic embolization on platelet values for liver cirrhosis patients with thrombocytopenia.
    Lee CM; Leung TK; Wang HJ; Lee WH; Shen LK; Liu JD; Chang CC; Chen YY
    World J Gastroenterol; 2007 Jan; 13(4):619-22. PubMed ID: 17278231
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of partial splenic arterial embolization for hypersplenism in patients with liver cirrhosis and thrombocytopenia.
    Abdella HM; Abd-El-Moez AT; Abu El-Maaty ME; Helmy AZ
    Indian J Gastroenterol; 2010 Mar; 29(2):59-61. PubMed ID: 20443100
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lusutrombopag Is Safe and Efficacious for Treatment of Thrombocytopenia in Patients With and Without Hepatocellular Carcinoma.
    Alkhouri N; Imawari M; Izumi N; Osaki Y; Ochiai T; Kano T; Bentley R; Trevisani F
    Clin Gastroenterol Hepatol; 2020 Oct; 18(11):2600-2608.e1. PubMed ID: 32205226
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thrombocytopenia in Chronic Liver Disease: New Management Strategies.
    Nilles KM; Flamm SL
    Clin Liver Dis; 2020 Aug; 24(3):437-451. PubMed ID: 32620282
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic factors considered according to the preoperative splenic volume for a prolonged increase in platelet count after partial splenic embolization for liver cirrhosis.
    Hayashi H; Beppu T; Okabe K; Masuda T; Okabe H; Ishiko T; Baba H
    J Gastroenterol; 2010 May; 45(5):554-9. PubMed ID: 20047119
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Partial splenic embolization in patients with cirrhosis: efficacy, tolerance and long-term outcome in 32 patients.
    N'Kontchou G; Seror O; Bourcier V; Mohand D; Ajavon Y; Castera L; Grando-Lemaire V; Ganne-Carrie N; Sellier N; Trinchet JC; Beaugrand M
    Eur J Gastroenterol Hepatol; 2005 Feb; 17(2):179-84. PubMed ID: 15674095
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Systematic Review with Meta-Analysis: Efficacy and Safety of Lusutrombopag for Severe Thrombocytopenia in Patients with Chronic Liver Disease Undergoing Invasive Procedures.
    Orme ME; Bentley R; Marcella S; Peck-Radosavljevic M; Perard R; Wedemeyer H; Yoshiji H; Agarwal K; Dusheiko G
    Adv Ther; 2022 Sep; 39(9):4169-4188. PubMed ID: 35836089
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Large splenic volume may be a useful predictor for partial splenic embolization-induced liver functional improvement in cirrhotic patients.
    Hayashi H; Beppu T; Masuda T; Okabe H; Imai K; Hashimoto D; Ikuta Y; Chikamoto A; Watanabe M; Baba H
    J Hepatobiliary Pancreat Sci; 2014 Jan; 21(1):51-7. PubMed ID: 23798315
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized controlled trial of lusutrombopag in Japanese patients with chronic liver disease undergoing radiofrequency ablation.
    Tateishi R; Seike M; Kudo M; Tamai H; Kawazoe S; Katsube T; Ochiai T; Fukuhara T; Kano T; Tanaka K; Kurokawa M; Yamamoto K; Osaki Y; Izumi N; Imawari M
    J Gastroenterol; 2019 Feb; 54(2):171-181. PubMed ID: 30105510
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Repeated Lusutrombopag Treatment for Thrombocytopenia in Patients with Chronic Liver Disease.
    Sano Y; Morimoto M; Kobayashi S; Ueno M; Fukushima T; Asama H; Kawano K; Nagashima S; Tanaka S; Ohkawa S; Maeda S
    Digestion; 2021; 102(4):654-662. PubMed ID: 32841939
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lusutrombopag for thrombocytopenia in Chinese patients with chronic liver disease undergoing invasive procedures.
    Ding Z; Wu H; Zeng Y; Kuang M; Yang W; Meng Z; Chen Y; Hao C; Zou S; Sun H; Liu C; Lin K; Shi G; Wang X; Fu X; Chen R; Chen Y; Liang R; Kano T; Pan H; Yang S; Fan J; Zhou J
    Hepatol Int; 2023 Feb; 17(1):180-189. PubMed ID: 36258065
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of severe thrombocytopenia in preventing platelet count recovery in thrombocytopenic patients with chronic liver disease.
    Hirooka M; Ochi H; Hiraoka A; Koizumi Y; Tanaka T; Sunago K; Yukimoto A; Imai Y; Watanabe T; Yoshida O; Abe M; Joko K; Michitaka K; Hiasa Y
    J Gastroenterol Hepatol; 2020 Feb; 35(2):299-304. PubMed ID: 31318996
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term evaluation of partial splenic embolization followed by interferon therapy in patients with hepatitis C virus (HCV) cirrhosis and thrombocytopenia.
    Shimizu H; Takatsuka K; Nakano H; Tenjin T; Fujikawa T; Yoshida A; Yoshimatsu E; Matsui K; Iwabuchi S
    Intern Med; 2014; 53(9):925-31. PubMed ID: 24785882
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Partial splenic embolization using polyvinyl alcohol particles for hypersplenism in cirrhosis: a prospective randomized study.
    Zhu K; Meng X; Li Z; Huang M; Guan S; Jiang Z; Shan H
    Eur J Radiol; 2008 Apr; 66(1):100-6. PubMed ID: 17532166
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Partial splenic embolization for hypersplenism in cirrhosis: a long-term outcome in 62 patients.
    Zhu K; Meng X; Qian J; Huang M; Li Z; Guan S; Jiang Z; Shan H
    Dig Liver Dis; 2009 Jun; 41(6):411-6. PubMed ID: 19070555
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.